Rectal Cancer Clinical Trial
Official title:
Volume-outcome Relationship in Rectal Cancer Surgery
Verified date | February 2021 |
Source | University of Rome Tor Vergata |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Hospital centralization effect is reported to lower complications and mortality especially for high risk and complex general surgery operations, including colorectal surgery. However, no linear relation between volume and outcome has been demonstrated. Aim of the study was to evaluate the increased surgical volume effect on early outcomes of patient undergoing restorative anterior rectal resection (ARR).
Status | Completed |
Enrollment | 187 |
Est. completion date | January 31, 2021 |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - diagnosis of a cancer located in the rectum, defined according to the international definition by D'Souza et al., - elective setting - anterior rectal resection with primary anastomosis (with or without diverting loop ileostomy). Exclusion Criteria: - age below age of 18, - inflammatory bowel disease, - acquired or congenital immunodeficiency, - preoperative infection, - pregnancy, - ASA IV, - presence of synchronous cancers, - abdominoperineal resection (APR), - failure to perform rectal resection and primary anastomosis, - emergency setting. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Rome Tor Vergata |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anastomotic leak | rate of any postoperative leakage of colo-rectal anastomosis clinically, radiologically or endoscopically demonstrated | up to 30 days after discharge | |
Secondary | Postoperative complications | rate of any surgical site infection clinically demonstrated | up to 30 days after discharge | |
Secondary | Surgical site infection | Rate of any complication after rectal resection | up to 30 days after discharge | |
Secondary | Pneumonia | rate of radiologically demonstrated pneumonia | up to 30 days after discharge | |
Secondary | Ileus | rate of any ileus clinically demonstrated | up to 30 days after discharge | |
Secondary | Bleeding | Rate of any clinically radiologically or endoscopically demonstrated bleeding after rectal resection | up to 30 days after discharge | |
Secondary | Reoperation | Rate of any reoperation | up to 30 days after discharge | |
Secondary | Readmission | Rate of any unplanned readmission after discharge | up to 90 days after discharge | |
Secondary | 30-days-mortality | Rate of any mortality | up to 30 days after discharge | |
Secondary | 1-year stoma persistence | rate of stoma persistence | up to one year after surgery | |
Secondary | Length of hospital stay | number of days between primary rectal resection and discharge | up to 30 days after discharge | |
Secondary | Use of minimally invasive approach | rate of minimally invasive rectal ARR performed | up to 30 days after discharge | |
Secondary | Operative time | Mean operative time | up to 30 days after discharge | |
Secondary | Conversion to open surgery | rate of conversion form laparoscopy to one surgery | up to 30 days after discharge | |
Secondary | need of postoperative blood transfusion | rate of postoperative transfusion | up to 30 days after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 |